Canntab Therapeutics
For Immediate Release
2020_09_21
CANNTAB GRANTED 1st US PATENT COVERINGMULTI-LAYER (BI-LAYER) TABLETS
TORONTO, September 21st, 2020/ – Canntab Therapeutics Limited (CSE
ILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leadinginnovator in cannabinoid and terpene blends in hard pill form for therapeuticapplications, is thrilled to announce that, pursuant to a filing made in March2017, the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No.10,772,837 to Canntab, titled “Modified Release Multi-Layer Tablet CannabinoidFormulations." The term of the patent expires on March 15, 2038.
Larry Latowsky, CEO of Canntab said “this is amajor milestone that confirms our proprietary formulations are unique anddifferentiated from other product offerings in the global marketplace whichwill support a faster revenue stream as we begin production and distribution inthe immediate future. This is the first patent that was issued to date out ofthe 13 that we have applied for, and will be leveraged to solidify Canntab’sposition as the leader in solid dose (hard pill) formulations of medicinalcannabinoids.
The patent granted is for Canntab’s bi-layeror multi-layer tablets consisting of both Instant Release (“IR”) and ExtendedRelease (‘XR”) formulations with THC, CBD and a variety of Terpenes and otherCannabinoids found in full spectrum Cannabis and Hemp oil resin.
Canntab believes that its hard pillformulations are superior to all other CBD and THC delivery systems since theyare true pharmaceutical grade delivery systems which provide for superioringredient stability, enhanced bioavailability, and provide customizable and precisedosing. Canntab believes and intends to prove greater bioavailability through ablood level study at a 3rd party Clinical Research Organization (CRO). Inaddition, whether it is for medical, recreational or nutraceutical purposes,Canntab is able to provide extended release formulations making it the cleardelivery choice for doctors, patients or the average consumer.
“Canntab expects this and future patents to bevery valuable in the development of our strategic partnerships and alliancesand in our efforts to secure worldwide distribution of our proprietaryproducts. As the medical community continues to recognize Cannabinoidalternatives to traditional therapies, we will continue to develop innovativeapproaches to support many clinical applications” continued Latowsky.
In addition, Canntab is conducting research toconfirm its belief that its combined CBD and THC tablet can be effective totreat nicotine, alcohol, cannabis, opioid and other forms of addiction. Canntabwill be using a derivative of these formulations for its clinical trial withDr. Donald Garbuz from the University of British Columbia and as previouslyreleased in December 2018. This study aims to demonstrate the potential for thereduction or elimination of the use of opiates in patients duringpost-operative pain management.
This issued patent covers Canntab’s modifiedrelease pharmaceutical compositions and more specifically compositionscomprising cannabinoids and a process for preparation thereof as well asmethods for administering the compositions to human users. The compositions maycontain a combination of ingredients in proportions calculated to achievetherapeutic effect.
Canntab has filed applications for 13 patentsin Canada and the United States that cover a range of processes andformulations that it uses to create its precision oral-delivery hard tablets,the future of medical cannabis. These patents include Canntab's proprietarynano-emulsification technology, granulation process, methods of manufacturing andcovers its full line of precision oral-delivery hard tablets including instant(immediate) release tablets, extended release tablets, oral dissolvabletablets. Canntab has also filed a patent for an exclusive formulation of THCand CBD for the treatment of opioid addiction treatment therapy.
